Original articleEpidemiology of Candida isolates from Intensive Care Units in Colombia from 2010 to 2013Epidemiología de aislamientos de Candida en unidades de cuidados intensivos en Colombia durante el período 2010–2013
Section snippets
Participating institutions
Data from the clinical isolates of Candida collected in ICUs of 20 tertiary healthcare institutions (that belong to the National Bacterial Resistance and HAIs Surveillance Network) between January 1st, 2010 and December 31st, 2013 were analyzed. Hospitals from the following Colombian cities were included: Barranquilla, Bogotá, Bucaramanga, Cali, Cúcuta, Ibagué, Medellín, Neiva, Pasto and Pereira. Most hospitals were private (n = 14) and teaching hospitals (n = 15) catalogued as medium size
Results
Between 2010 and 2013, 44,438 microbiological isolates, including bacteria and fungi, were reported; 2680 (6%) corresponded to fungi. Out of these, 2533 (94.5%) belonged to Candida genus (Table 1). During the study period C. albicans and non-C. albicans Candida species had similar proportions (48.3% and 51.7% respectively) and did not present significant differences over time (p = 0.24/Wilcoxon Mann–Whitney test) (Fig. 1). The most prevalent species among the non-C. albicans Candida species were
Discussion
Fungal infections are challenging healthcare infections in critically-ill patients due to the difficulty in diagnosis and empirical management; these infections are usually associated with increased rates of morbidity and mortality. Candida species are the third most frequent cause of bloodstream infections in ICU50 and the main clinical presentation is invasive candidiasis (IC). Prolonged length of stay, presence of invasive devices, major burn injuries, hemodialysis, neutropenia, bone-marrow
Funding
This study was partially supported by research grants from Merck Sharp & Dohme (FC-000687-2012) and Pfizer S.A. (FC-000583-2012). Merck Sharp & Dohme., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) and Pfizer S.A. had no influence on designing and writing the protocol, the collection of the data, performing the analysis of the results, or the writing of the manuscript.
Conflict of interest
Dr. Christian Pallares is a speaker for Pfizer SA, Merck Colombia S.A. and Merck Sharp & Dohme. Dr. José Oñate is a speaker for Pfizer S.A. and Merck Colombia S.A. Cristhian Hernandez is speaker for Merck Sharp & Dohme. Dr. Villegas is a consultant or speaker for Merck Sharp & Dohme, Merck Colombia S.A. and Pfizer S.A., and received research grants for the conformation of the network from Merck Sharp & Dohme, Merck Colombia S.A. and Pfizer S.A.
The other authors declare no conflicts of interest
Acknowledgments
We thank the people from the participant institutions and hospitals (2010–2013): Bogotá (Guillermo Prada, Stella Vanegas, Adriana Merchan, Henry Mendoza, Francisco Ortiz, Marta Patricia Meléndez, Carlos Álvarez, Sandra Valderrama, Katherine Gómez, Carlos Pérez, Julián Escobar, Luz Ángela Pescador, Sandra Gualtero, Gerson Arias), Cali (Leonor Dicué, Sandra Ossa, Martín Muñoz, Fernando Rosso, Marly Orrego, Lorena Matta, Socorro Trujillo), Pereira (Carmen Elisa Llanos, Berenice Isaza), Pasto
References (54)
- et al.
Guidelines for the treatment of invasive candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 update
Enferm Infecc Microbiol Clin
(2011) - et al.
Candida colonization of the respiratory tract and subsequent Pseudomonas ventilator-associated pneumonia
Chest
(2006) - et al.
Fungal bloodstream infections in tertiary care hospitals in Colombia
Rev Iberoam Micol
(2011) - et al.
Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK
Int J Infect Dis
(2011) - et al.
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Lancet Infect Dis
(2003) - et al.
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage
J Infect
(2008) Global trends in the distribution of Candida species causing candidemia
Clin Microbiol Infect
(2014)- et al.
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
J Hosp Infect
(2002) - et al.
European expert opinion on the management of invasive candidiasis in adults
Clin Microbiol Infect
(2011) Invasive candidiasis
Infect Dis Clin North Am
(2006)
Emergence of Candida parapsilosis candidemia at Cochin hospital. Characterization of isolates and search for risk factors
Pathol Biol (Paris)
Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values
Diagn Microbiol Infect Dis
European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region
J Hosp Infect
Candida peritonitis
Enferm Infecc Microbiol Clin
Fungal infections in the ICU
Infect Dis Clin North Am
The case for antifungal stewardship
Curr Opin Infect Dis
Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome
Med Mycol
Epidemiological trends in nosocomial candidemia in intensive care
BMC Infect Dis
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality
Intensive Care Med
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit
J Antimicrob Chemother
Echinocandins for candidemia in adults without neutropenia
N Engl J Med
Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers
J Clin Microbiol
Incidence and prevalence of candidemia in critically ill patients in Colombia
Rev Chilena Infectol
Clinical and epidemiological characteristics and risk factors for mortality in patients with candidemia in hospitals from Bogota, Colombia
Braz J Infect Dis
Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth informational Supplement. CLSI document M27-S4
Candida peritonitis: an update on the latest research and treatments
World J Surg
Cited by (21)
Frequency and co-colonization of vancomycin-resistant Enterococci and Candida in ICU-hospitalized children
2021, New Microbes and New InfectionsCitation Excerpt :As demonstrated by the results, out of 205 patients included in the present study, 44 (21.5%) were positive for Candida infections. These results were in contrast to the previously published studies of Rahbar et al. from Iran [30], Motoa et al. from Colombia [31], Kumar et al. from India [32], Alimehr et al. from Iran [33] and Comert et al. from Turkey [34]. These studies recorded frequencies of Candida species in the ICU ward of 12%, 5.7%, 57.3%, 12%, and 6.6%, respectively.
Candida parapsilosis complex in veterinary practice: A historical overview, biology, virulence attributes and antifungal susceptibility traits
2017, Veterinary MicrobiologyCitation Excerpt :Despite these reports of Candida infection in animals, epidemiological data on localized and systemic Candida infections are not fully available yet. Among the different species of Candida, C. parapsilosis has emerged as an important agent of candidiasis in humans, with emphasis on candidemia, since it is a frequent agent of Candida bloodstream infections in the USA (Suhr et al., 2017), Latin America (Lockhart et al., 2008; Motoa et al., 2017), Europe (Lockhart et al., 2008; Lovero et al., 2016; Tadec et al., 2016), Turkey (Ulu-Kilic et al., 2016) and Israel (Eliakim-Raz et al., 2016). In Brazil, C. parapsilosis sensu lato is responsible for 15–30% of these infections (Colombo et al., 2013).
Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2<sup>®</sup> and Sensititre YeastOne<sup>®</sup>
2018, Revista Iberoamericana de Micologia